IP In Systems Biology

Patenting your personalised medicine innovations to change the concept of biomedical care.

Date: September 19, 2006

Venue: Radisson SAS Scandinavia Hotel

City: Copenhagen, Denmark

In the Chair:

Dr. Kári Stefánsson
President and Chief Executive Officer
DECODE GENETICS

Hear from your eminent Speaker Panel:

Jay Z. Zhang
Vice President of Intellectual Property
MYRIAD GENETICS, INC. (USA)

Dr. Gerald V. Dahling
Senior Vice President Global Patents
SANOFI-AVENTIS

Allen Norris
Vice President and Head of Group Intellectual Property
UCB GROUP

Thomas Malone Ph.D.
J. D. Senior IP Counsel
AFFYMETRIX, INC. (USA)

Stephen K. Boyer Ph.D.
Senior Scientist
IBM HEALTHCARE & LIFE SCIENCES

Bernd Isert
Director - Biotechnology
EUROPEAN PATENT OFFICE

Gerry Kamstra
Partner IP & Life Sciences
BIRD & BIRD

Neil Jenkins
Partner IP & Life Sciences
BIRD & BIRD

Elizabeth A. Doherty, Ph.D.
Patent Attorney
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER

Peter Horn Møller, Ph.D.
Partner and Head of Life Science and Chemistry
Plougmann & Vingtoft

Nicka Kirstejn Johansen M.Sc. Biology
Patent Attorney
PLOUGMANN & VINGTOFT

Event Summary:

We are facing a paradigm shift in the global life science industry today. Personalised medicines allow biotech and pharmaceutical companies to deliver customised drugs or treatment options that match each individual's genetic make-up. To be at the forefront your company needs to master the IP strategies successfully in an emerging field of pharmaceutics.

The driving force behind this radical transformation is the mapping of the human genome and its combination with proteomics in the human body.

It is important to develop an IP strategy focusing on your personalised medicine innovations where genomic relationships are being used to customise a drug for specific target diseases. The key to success is the combination. Narrow claims protect your biotech invention and will successfully exclude your competitors to exploit the claimed genomic relationship in your patents.

This international flagship event will present the IP leaders within personalised medicine providing your company with an IP platform to protect your personalised medicine innovations in the era of post-genomics. Our high level speaker panel will guide you through the steps required to protect your company's most valuable assets, the patents.

This conference will tackle key issues such as:

Designing an IP strategy to protect your personalised medicine inventions
Mastering your patent strategy to launch a group of personalised medicines
What personalised medicine patents can be listed?
Personalised medicine patents: Narrow vs. broad claims to maximise your freedom to operate?
Mastering IP vision and strategy to speed up the development of personalised drugs and diagnostics
Capitalising on Systems Biology to ensure freedom to operate in the field of personalised medicines
Seeking patent protection during the pre-approval process for your customised drugs and treatment methods
How do you protect your personalised medicine inventions?
Establishing partnerships and licensing to customise your diagnostics applications in a growing market
Ensuring regulatory approval to launch inventions to your consumer groups
How do you enforce your innovations in an emerging field of pharmaceutics

Target audience and Job Titles:

Presidents, Chief Executive Officers, Chief IP Counsels, Chief Scientific Officers, Vice Presidents, Directors and Heads of:

Intellectual Property
Corporate Patents
Global Intellectual Property
Corporate Intellectual Property
Corporate Patents and Trade Marks
Patents - Biotechnology
IPR Strategy
Legal and Intellectual Property
Patents
Pharmaceutical Patents
European Patent Attorneys
Patent Agents
Research & Development
Systems Biology
Business Development
Venture Capitalists
Partners
Consultants